A year to remember: Celebrating Bowel Cancer UK's successful partnership with the BIA

Kelsey Lawrence .png

In this blog, Kelsey Lawrence, the Senior Corporate Partnerships Officer for Bowel Cancer UK, reflects on the highlights of the charity partnership with BIA during 2023. She concludes by extending gratitude to members and all who made the partnership impactful. 

On behalf of the Bowel Cancer UK team, thank you to everyone in the BIA community for embracing us so warmly and making this partnership such a success. As the Senior Corporate Partnerships Officer for Bowel Cancer UK, I’ve had the great privilege to get to work alongside your brilliant organisation. I’m so proud of what we’ve achieved together and wanted to take a moment to look back on our amazing year.

At the heart of our partnership was a touching tribute to the late Aisling Burnand CBE, someone who was deeply connected to Bowel Cancer UK and the BIA. Aisling's legacy became a driving force behind our work together and inspired our shared commitment to transforming the treatment and care for bowel cancer patients. As well as being a previous CEO of the BIA she was also a valued trustee of our charity who is greatly missed. We know that she’d be proud to see everything we’ve achieved together.

The year started in style with the annual BIA Gala Dinner. The flagship event saw 650 of you from across the BIA membership come together in London, for networking and captivating speeches, including from Dr Anisha Patel. Anisha shared her unique and moving perspective as both a bowel cancer patient and GP, honestly recounting the turbulent reality of living with and beyond the disease. Thanks to the incredible generosity of attendees, we raised over £30,000 on the night.   

Another highlight was the brand new '5 Biotech Wonders of the World' challenge. Teams leapt at the chance to cover long virtual distances from the BIA office in London to five Biotech hubs around the world. Excitingly after many days of fierce competition to cover the furthest distance, and raise the most money, team MaxCyte Sparks ultimately triumphed with Team Astex Athletes in second place and Gallagher Life Sciences Practice coming in third. Your collective efforts of walking, running, swimming, and cycling not only reached impressive distances but also symbolized the journey we’re making to a world where no one dies from bowel cancer.

Thanks to your determined support, an amazing sum of over £70,000 was raised for Bowel Cancer UK's crucial work making this one of the biggest charity partnerships we have had to date. This incredible sum of money will have a big impact and is enough to fund three pilot grants to test innovations that help patients get earlier diagnoses and improve their chances of survival.

Your support means we can help more people like Clare access new and innovative treatments that are right for them: “I think the statistics for people like me diagnosed with stage 4 bowel cancer are appalling. I want to help make sure others don't get the news I have, and research is the only way to improve treatments and find ways to prevent it too."

We’ve thoroughly enjoyed being part of the membership this year and have had the pleasure of meeting so many of you, hearing about your work and exploring ways we can work together. If you’d like to explore ways we can partner in the future, I’d be delighted to hear from you via [email protected] to continue to deepen the legacy of our partnership.

Thank you.


More news and updates

CEO Update - 10 June 2024

UK General Election and what it might mean for the industry, including Labour's pledges on Brexit and business taxes. Upcoming events including the Cambridge Wide Open Day and the Life Science Leadership Summit. UK tech companies pitching at the London Stock Exchange and Amber Therapeutics securing $100 million in funding.

Women in Biotech Mentoring Programme: Dr Carolina Grandellis

In this interview, Dr Carolina Grandellis, Lead of the Earlham Institute Biofoundry, explores the profound impact of the BIA's Women in Biotech mentoring programme on her professional and personal life.

An urgent call for technical standards and metrics for engineering biology

There are currently very few technical standards and metrics that are specific and appropriate to the field of engineering biology. Across the innovation pipeline, there are opportunities for standards to support faster development and enable accelerated commercialisation of the bioeconomy. In response to this, an effort was undertaken with the objective of identifying key areas where standards and metrics would enable the growth of the global bioeconomy.

CEO Update - 3 June 2024

MSD Merck acquire UK biotech EyeBio for $1.3 billion upfront, ASCO and BIO conference week and the UK General election campaign produces little news for the life science sector.

CEO Update - 28 May 2024

The UK General Election has been called for Thursday, 4 July. In practical terms, this means the end of the legislative pathway for many proposals as Parliament shuts down. Keep reading for updates on our general election webinars and UK events at BIO 2024.

CEO Update - 20 May 2024

The UK continues to lead the global discussion on tackling the antibiotic emergency. Last week saw leading global figures convene at the Royal Society to pledge money and agree actions on the AMR agenda.

Spotlight on hearing therapeutics landscape: a clinical perspective

Professor Gerard O’Donoghue shares his perspective as Consultant Neurotologist at Nottingham University Hospitals NHS Trust on why he believes that the development of new treatments and their subsequent clinical adoption are vital for people living with hearing loss.

Deep Biotech companies using engineering biology for good: Epoch Biodesign case study

Featured in BIA's Deep Biotech report, Epoch Biodesign aims to revolutionize plastic waste management by creating tailor-made enzymes that efficiently depolymerize a wide range of plastics into recyclable materials, offering a circular solution to tackle plastic pollution and promote sustainability.

Women in Biotech Mentoring Programme: Helen and Kathryn's experience

In this interview, consultant and best-selling author Kathryn Simpson, together with patent attorney Helen Bartlett, dive into their reasons for joining the BIA's Women in Biotech mentoring programme, and how this experience has impacted their professional and personal lives.

Deep Biotech companies using engineering biology for good: Solena Materials case study

Solena Materials is a pioneering biotech company spun out from Imperial College London, specialising in the development of computationally designed synthetic protein materials, originally featured in BIA's Deep Biotech report on disruptive innovation for global sustainability.


More within